84944-15-0Relevant articles and documents
Structure-activity relationship study of a series of caspase inhibitors containing γ-amino acid moiety for treatment of cholestatic liver disease
Mou, Jianfeng,Wu, Songliang,Luo, Zhi,Guo, Fengying,He, Haiying,Wang, Jianhua,Lin, Fusen,Guo, Fengxun,Sun, Jianping,Shen, Liang,Zeng, Minggao,Wang, Chuan,Xu, Deming,Gu, Zhengxian,Tian, Xin,Zhang, Aiming,Xu, Hongjiang,Yang, Ling,Zhang, Xiquan,Li, Jian,Chen, Shuhui
supporting information, p. 1874 - 1878 (2018/04/12)
A series of caspase inhibitors containing γ-amino acid moiety have been synthesized. A systemic study on their structure-activity relationship of anti-apoptotic cellular activity is presented. These efforts led to the discovery of compound 20o as a potent caspase inhibitor, which demonstrated preclinical ameliorating total bilirubin efficacy with a significantly improved pharmacokinetic profile.
First-in-class pan caspase inhibitor developed for the treatment of liver disease
Linton, Steven D.,Aja, Teresa,Armstrong, Robert A.,Bai, Xu,Chen, Long-Shiuh,Chen, Ning,Ching, Brett,Contreras, Patricia,Diaz, Jose-Luis,Fisher, Craig D.,Fritz, Lawrence C.,Gladstone, Patricia,Groessl, Todd,Gu, Xin,Herrmann, Julia,Hirakawa, Brad P.,Hoglen, Niel C.,Jahangiri, Kathy G.,Kalish, Vincent J.,Karanewsky, Donald S.,Kodandapani, Lalitha,Krebs, Joseph,McQuiston, Jeff,Meduna, Steven P.,Nalley, Kip,Robinson, Edward D.,Sayers, Robert O.,Sebring, Kristen,Spada, Alfred P.,Ternansky, Robert J.,Tomaselli, Kevin J.,Ullman, Brett R.,Valentino, Karen L.,Weeks, Suzanne,Winn, David,Wu, Joe C.,Yeo, Pauline,Zhang, Cheng-Zhi
, p. 6779 - 6782 (2007/10/03)
A series of oxamyl dipeptides were optimized for pan caspase inhibition, anti-apoptotic cellular activity and in vivo efficacy. This structure-activity relationship study focused on the P4 oxamides and warhead moieties. Primarily on the basis of in vitro data, inhibitors were selected for study in a murine model of α-Fas-induced liver injury. IDN-6556 (1) was further profiled in additional in vivo models and pharmacokinetic studies. This first-in-class caspase inhibitor is now the subject of two Phase II clinical trials, evaluating its safety and efficacy for use in liver disease.
